Medicamen Biotech
Medicamen Biotech Share Price Chart
Medicamen Biotech last traded at ₹300.10 (2026-10-13). Over the past month the stock moved -0.3%, three months the stock moved +10.6%, year the stock moved -10.1%. Its closing range over 52 weeks is ₹218.55 – ₹411.35, with the latest close 27.0% below the high.
Closing prices up to 2026-10-13.
About Medicamen Biotech
Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations[1]
Business Overview:[1][2][3] MBL, a subsidiary of Shivalik Rasayan Ltd with 41.6% ownership, is an integrated Pharmaceutical and Life Sciences Solution Provider. They manufacture pharmaceutical formulations, primarily focusing on oncology therapeutics and generics, distributed through wholesale drug distributors and sold to institutional segments such as government and semi-government institutions, and hospitals. Their formulations cover beta-lactam, non-beta-lactam, and cephalosporin drugs for overseas and domestic markets.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Medicamen Biotech reported sales of ₹43.85 crore (+14.0%) and net profit of ₹2.53 crore (+54.3%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 43.85 | 4.78 | 10.90 | 2.53 | 1.87 |
| Mar 2026 | 54.68 | 4.12 | 7.53 | 2.97 | 2.19 |
| Dec 2025 | 43.49 | 5.08 | 11.68 | 2.59 | 1.91 |
| Sep 2025 | 42.23 | 5.05 | 11.96 | 2.21 | 1.63 |
| Jun 2025 | 38.45 | 4.03 | 10.48 | 1.64 | 1.21 |
| Mar 2025 | 26.00 | -1.10 | -4.23 | 2.41 | 1.90 |
| Dec 2024 | 41.14 | 6.24 | 15.17 | 2.52 | 1.98 |
| Sep 2024 | 42.84 | 6.55 | 15.29 | 2.27 | 1.79 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +0.4% | -6.9% | -42.2% | -7.3% | -1.4% | +5.7% | +110.3% | +14.0% |
| Operating profit growth | +6.3% | +11.6% | -116.1% | -17.1% | -22.9% | -18.6% | – | +18.6% |
| Net profit growth | -24.6% | -9.0% | -22.3% | -27.4% | -2.6% | +2.8% | +23.2% | +54.3% |
| EPS growth | -24.8% | -9.6% | -22.1% | -32.0% | -8.9% | -3.5% | +15.3% | +54.5% |
| OPM % | 15.3% | 15.2% | -4.2% | 10.5% | 12.0% | 11.7% | 7.5% | 10.9% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Medicamen Biotech reported sales of ₹179.00 crore (+9.8%) and net profit of ₹9.00 crore (+28.6%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 179.00 | 18.00 | 10.00 | 9.00 | 6.94 |
| Mar 2025 | 163.00 | 14.00 | 9.00 | 7.00 | 5.59 |
| Mar 2024 | 179.00 | 24.00 | 13.00 | 9.00 | 8.60 |
| Mar 2023 | 141.00 | 24.00 | 17.00 | 15.00 | 11.73 |
| Mar 2022 | 115.00 | 24.00 | 21.00 | 15.00 | 12.20 |
| Mar 2021 | 113.00 | 20.00 | 17.00 | 12.00 | 9.93 |
| Mar 2020 | 125.00 | 20.00 | 16.00 | 13.00 | 10.88 |
| Mar 2019 | 123.00 | 17.00 | 14.00 | 12.00 | 10.28 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +9.8% | +1.6% | -9.6% | +1.8% | +22.6% | +27.0% | -8.9% | +9.8% |
| Operating profit growth | +0.0% | +17.6% | +0.0% | +20.0% | +0.0% | +0.0% | -41.7% | +28.6% |
| Net profit growth | +20.0% | +8.3% | -7.7% | +25.0% | +0.0% | -40.0% | -22.2% | +28.6% |
| EPS growth | +15.6% | +5.8% | -8.7% | +22.9% | -3.9% | -26.7% | -35.0% | +24.2% |
| OPM % | 14.0% | 16.0% | 17.0% | 21.0% | 17.0% | 13.0% | 9.0% | 10.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Medicamen Biotech.
Get Free AI Stock Analysis FREE →Latest News
No recent news available for Medicamen Biotech.
Frequently Asked Questions
What is the share price of Medicamen Biotech today?
Medicamen Biotech shares were last quoted at ₹300.10 (-0.2% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Medicamen Biotech?
Medicamen Biotech has a price-to-earnings (P/E) ratio of 39.98 and a price-to-book (P/B) ratio of 1.56. The industry P/E is 53.33.
What is the 52-week high and low of Medicamen Biotech?
The 52-week high of Medicamen Biotech is ₹454.00 and the 52-week low is ₹210.10.
What is the market cap of Medicamen Biotech?
The market capitalisation of Medicamen Biotech is about ₹432.78 crore.
How did Medicamen Biotech perform in its latest quarterly results?
In the latest quarter (Jun 2026), Medicamen Biotech reported sales of ₹43.85 crore (+14.0%) and net profit of ₹2.53 crore (+54.3%), compared with the same quarter last year.
Is Medicamen Biotech a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Medicamen Biotech has a 3-year ROE of 5.00%, 3-year profit growth of -14.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Medicamen Biotech?
Promoters hold about 40.46% of Medicamen Biotech.
Which sector does Medicamen Biotech belong to?
Medicamen Biotech belongs to the Pharmaceuticals & Drugs sector.